News

94% of patients suing Merck over rofecoxib agree to company’s offer

BMJ 2008; 336 doi: 10.1136/bmj.39513.541296.DB (Published 13 March 2008)
Cite this as: BMJ 2008;336:580.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Fred Charatan
  1. 1Florida

    A large enough proportion of the litigants suing Merck after taking the drug rofecoxib (Vioxx) have agreed to the terms of the company’s offer to allow the settlement to go ahead.

    Eighty five per cent of claimants had to agree to the settlement to proceed, and by the beginning of this month 94% (44 000 of the 47 000) had done so. The company announced in November a settlement worth $4.85bn (£2.41bn; €3.15bn).

    The individual awards, estimated at $150 000 to $200 000 on average, will be …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular